Videos
The company’s proprietary Verisome drug delivery technology is being used as the base for IBI-10090, for post-cataract surgery inflammation. The dexamethasone compound completed a pivotal…
Read MoreBy penetrating the mucosal barrier in the eye, Kala’s Mucosal Penetrating Products (MPPs) “enhances pharmacokinetics” and can be used to treat both anterior and posterior…
Read MoreENV515 is a proprietary, fully biodegradable PRINT (Particle Replication In Non-Wetting Templates) particle formulation of a prostaglandin analog, travoprost, with the potential for sustained intraocular…
Read MoreParticipant: Eric Donnenfeld, MD Eric Donnenfeld, MD is a founding partner of Ophthalmic Consultants of Long Island, Professor of Ophthalmology NYU and a Trustee at…
Read MoreThe CyPass Micro-Stent has been implanted in more than 1,000 patients over the course of 10 years as part of multiple clinical trials, and Transcend…
Read MoreParticipants: Eric Donnenfeld, MD Eric Donnenfeld, MD is a founding partner of Ophthalmic Consultants of Long Island, Professor of Ophthalmology NYU and a Trustee at…
Read MoreParticipant: Kuldev Singh, MD, MPH Dr. Kuldev Singh is Professor of Ophthalmology and Director of the Glaucoma Service at the Stanford University School of Medicine.…
Read MoreJade’s proprietary, cross-linked, bioerodable hydrogel technology can be used alone as an ocular lubricant, or as a sustained-release vehicle for either anterior or posterior segments.…
Read MoreThe company’s LacriPen is a handheld, portable, diagnostic tool that measures osmolarity to within 2 mOsml. It uses a technique called surface plasma residence, which…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")